All In Biotech

Drug Trial Radar · NCT06774664

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTC21C in Subjects With Plasma Cell-driven Autoimmune Diseases

Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Jan 2025

Primary completion

Sep 2027

Study completion Mar 2029

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Jan 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases

Conditions

  • IgA Nephropathy

Interventions

  • SCTC21CBiological

    Drug: SCTC21C Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Treatment-emergent adverse events (TEAEs), serious adverse events (SAEs).Time frame: 36 Weeks
  2. Phase 2: Percentage change in urine protein-to-creatinine ratio (UPCR) at Week 24 compared to baselineTime frame: 24 Weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Baotou Medical College

    Baotou, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • Sichuan Academy of Medical Sciences - Sichuan Provincial People's Hospital

    Chengdu, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • The First Affliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • Shandong Provincial Hospital

    Jinan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China

  • Guangxi Zhuang Autonomous Region People's Hospital

    Nanning, China

  • Ningbo NO.2 Hospital

    Ningbo, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Shanghai General Hospital

    Shanghai, China

  • Wuxi People's Hospital

    Wuxi, China

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi'an, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

  • The Second Affiliated Hospital of Xingtai Medical College

    Xingtai, China

  • Yantai Yuhuangding Hospital

    Yantai, China

  • General Hospital of Ningxia Medical University

    Yinchuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.